Encephalomyelitis – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Encephalomyelitis – Pipeline Review, H2 2017’, provides an overview of the Encephalomyelitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Encephalomyelitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Encephalomyelitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Encephalomyelitis

The report reviews pipeline therapeutics for Encephalomyelitis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Encephalomyelitis therapeutics and enlists all their major and minor projects

The report assesses Encephalomyelitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Encephalomyelitis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Encephalomyelitis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Encephalomyelitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aurigene Discovery Technologies Ltd

Biovista Inc

Grifols SA

Hemispherx Biopharma Inc

Johnson & Johnson

K-Pax Pharmaceuticals Inc

Momenta Pharmaceuticals Inc

Philogen SpA

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Encephalomyelitis - Overview

Encephalomyelitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Encephalomyelitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Encephalomyelitis - Companies Involved in Therapeutics Development

Aurigene Discovery Technologies Ltd

Biovista Inc

Grifols SA

Hemispherx Biopharma Inc

Johnson & Johnson

K-Pax Pharmaceuticals Inc

Momenta Pharmaceuticals Inc

Philogen SpA

Encephalomyelitis - Drug Profiles

alpha-1 proteinase inhibitor (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alpha-1 proteinase inhibitor (recombinant) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FR-104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JM-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KPAX-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-254 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Preimplantation Factor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PSA-20 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rintatolimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Chronic Fatigue Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize ROR-Gamma for Inflammation and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tetravil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

thymulin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WEHI-345 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Encephalomyelitis - Dormant Projects

Encephalomyelitis - Product Development Milestones

Featured News & Press Releases

May 31, 2017: Hemispherx Biopharma Enhances Ampligen Manufacturing and Scientific Capabilities

May 31, 2017: Hemispherx Biopharma Repurposes Ampligen in Immuno-Oncology

Oct 31, 2016: Hemispherx Biopharma Announces Identification of High Responder Patient Subgroup from Ampligen Phase III Trial in Patients with CFS/ME

Aug 23, 2016: Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic

Jul 27, 2016: Hemispherx Biopharma Reaches Agreement with Avrio Biopharmaceuticals for the Accelerated Production of Ampligen

Jun 07, 2016: Hemispherx Biopharma: Dr. William M. Mitchell Publishes Article Titled, “Efficacy of Rintatolimod in the Treatment of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)” in Expert Review of Clinical Pharmacology

Mar 10, 2016: Hemispherx Biopharma Reviews Ampligen Data with National Institute of Neurological Disorders and Stroke

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Encephalomyelitis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Encephalomyelitis – Pipeline by Aurigene Discovery Technologies Ltd, H2 2017

Encephalomyelitis – Pipeline by Biovista Inc, H2 2017

Encephalomyelitis – Pipeline by Grifols SA, H2 2017

Encephalomyelitis – Pipeline by Hemispherx Biopharma Inc, H2 2017

Encephalomyelitis – Pipeline by Johnson & Johnson, H2 2017

Encephalomyelitis – Pipeline by K-Pax Pharmaceuticals Inc, H2 2017

Encephalomyelitis – Pipeline by Momenta Pharmaceuticals Inc, H2 2017

Encephalomyelitis – Pipeline by Philogen SpA, H2 2017

Encephalomyelitis – Dormant Projects, H2 2017

Encephalomyelitis – Dormant Projects, H2 2017 (Contd..1), H2 2017

List of Figures

List of Figures

Number of Products under Development for Encephalomyelitis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports